News & CommentClinical Trials

Fraud and Ethics Charges Hit Stroke Drug Trial

See allHide authors and affiliations

Science  20 Dec 1996:
Vol. 274, Issue 5295, pp. 2004-2005
DOI: 10.1126/science.274.5295.2004

Summary

Amsterdam, the Netherlands—The Second European Stroke Prevention Study, a major clinical trial of a drug to prevent repeat strokes, has become mired in controversy. A paper describing promising results from the trial, published earlier this month, was originally turned down by The Lancet in part because of ethical concerns over the use of placebos, and it has been further tainted by allegations that fabricated data led to the disqualification of information on more than 400 patients.